Frischknecht, Lukas <br/><br/>
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.  [electronic resource] 

 -  The Journal of thoracic and cardiovascular surgery  Jun 2015 
 - 1539-46.e1 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-685X 
<br/><br/><label>Standard No.: </label>10.1016/j.jtcvs.2015.01.065  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--analysis<br/>Chemotherapy, Adjuvant<br/>DNA-Binding Proteins--analysis<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Disease-Free Survival<br/>Endonucleases--analysis<br/>Female<br/>Glutamates--administration & dosage<br/>Guanine--administration & dosage<br/>Humans<br/>Immunohistochemistry<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--enzymology<br/>Male<br/>Mesothelioma--enzymology<br/>Mesothelioma, Malignant<br/>Middle Aged<br/>Multivariate Analysis<br/>Neoadjuvant Therapy<br/>Neoplasm Recurrence, Local<br/>Neoplasm Staging<br/>Pemetrexed<br/>Platinum Compounds--administration & dosage<br/>Pleural Neoplasms--enzymology<br/>Pneumonectomy<br/>Predictive Value of Tests<br/>Proportional Hazards Models<br/>Ribonucleoside Diphosphate Reductase<br/>Risk Factors<br/>Time Factors<br/>Tissue Array Analysis<br/>Treatment Outcome<br/>Tumor Suppressor Proteins--analysis<br/>Gemcitabine